WO2004018453A1 - Derive de proline - Google Patents

Derive de proline Download PDF

Info

Publication number
WO2004018453A1
WO2004018453A1 PCT/JP2003/010548 JP0310548W WO2004018453A1 WO 2004018453 A1 WO2004018453 A1 WO 2004018453A1 JP 0310548 W JP0310548 W JP 0310548W WO 2004018453 A1 WO2004018453 A1 WO 2004018453A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
pyrrolidine
methyl
piperazinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2003/010548
Other languages
English (en)
Japanese (ja)
Inventor
Masahiro Fujita
Masato Sakamoto
Nobuhiko Horiuchi
Takayoshi Yamamoto
Kyoji Tomita
Kazuhiro Mizuno
Toshiyuki Niga
Hideaki Ito
Shigeki Kashimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Dainippon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2002242795A external-priority patent/JP2006052138A/ja
Priority claimed from JP2002339200A external-priority patent/JP2006052139A/ja
Priority claimed from JP2003027010A external-priority patent/JP2006052140A/ja
Application filed by Dainippon Pharmaceutical Co Ltd filed Critical Dainippon Pharmaceutical Co Ltd
Priority to AU2003257637A priority Critical patent/AU2003257637A1/en
Publication of WO2004018453A1 publication Critical patent/WO2004018453A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a novel proline derivative useful as a medicine and an intermediate for producing the same. More specifically, the present invention relates to a proline derivative or a salt thereof, a production intermediate thereof, a medicament, and a pharmaceutical composition having an excellent antibacterial activity, particularly against multidrug-resistant bacteria.
  • MRSA Methicilin-resistant Staphylococcus aureus
  • MRSA infectious disease 196 Intractable postoperative infection, first reported in the UK in 1961, in the respiratory and gastrointestinal tracts.
  • MRSA infectious disease prevailed in Europe and the United States in the late 1960s and late 1970s, and in Japan in the 1980s, attracted public attention as the main causative agent of hospital-acquired infections. It spread nationwide in the late 990s, and MRSA is now highly resistant to multiple drugs and resistant to the antibacterial agents Vancomycin and Arbekacin in MRSA infections. Strains have also emerged.
  • multidrug-resistant bacteria that have attracted a great deal of interest in the medical community include Penicillin-Resistant Streptococcus pneumoniae (PRSP) and Vancomycin-Resistant Enterococcus faeciwn
  • PRSP Penicillin-Resistant Streptococcus pneumoniae
  • Vancomycin-Resistant Enterococcus faeciwn pneumococcus is a pneumonia-causing bacterium that is feared for its virulence
  • enterococci are systemic infections and Z or urine that may be clinically isolated with MRSA.
  • new antibacterial agents such as quinoquinone and oxazolidinone are used, but their antibacterial activities are not so strong. The emergence of strains resistant to these antibiotics has also been reported.
  • the present inventors searched for a compound having a strong antibacterial activity against these multidrug-resistant bacteria, particularly MRSA, and succeeded in selecting a proline derivative described later, thus completing the present invention.
  • the present invention relates to a proline derivative represented by the following formula or a salt thereof.
  • ring A has 1 to 4 hetero atoms as ring constituent atoms, and is a halogen atom. It is a 5- to 6-membered heterocyclic group that may be condensed with an optionally substituted benzene ring.
  • p1 is an integer of 0 or 1
  • p2 is an integer of 0 or 1
  • p3 is an integer of 0 or 1.
  • Ri, R 2 and R 3 are bonded at any position on the A ring, and are the same or different and each has 1 to 3 halogen atoms or hydroxy groups (the hydroxy groups are protected with an acyl group). May be substituted with a lower alkyl group, a hydrogen atom, a lower alkoxy group, a lower alkylthio group, a halogen atom, a hydroxy group, an amino group, or an aminocarbonyl group (the amino group is protected or lower alkyl).
  • a saturated cyclic group (a) which is directly bonded to the A ring, or bonded via a carbonyl group, an imino lower alkylene or an oxy lower alkylene; It may contain two hetero atoms, and the cyclic group (a) may be substituted with a lower alkyl group optionally substituted with a halogen atom or a halogen atom.
  • T represents a single bond, a methylene group or a heptonyl group.
  • R 4 and R 5 may be the same or different and each may be a hydrogen atom or a lower alkyl group, or both bonded to the same carbon atom may be combined to form an oxo group.
  • n is an integer of 1 or 2.
  • R 6 and R 7 are the same or different and are a hydrogen atom, a hydroxy group, a halogen atom, a lower alkyl group, a phenyl group, a lower alkoxy group, a phenyl lower alkyloxy group, an amino group which may be protected, Both may combine to form a saturated cyclic group.
  • X is a carbon atom (CH 2 , CH, C), a zeo atom or an oxygen atom, and n is an integer of 1 or 2.
  • Y is a hydrogen atom or an amino protecting group or a group (b) represented by the following formula.
  • R 8 is an alkyl group or a cycloalkyl lower alkyl group
  • R 9 is a hydrogen atom or a hydroxy protecting group, or R 9a .
  • R 9a is R 9al -CO-
  • R 9a2 -0- CO-
  • R 9al is a lower alkyl group (the lower alkyl group is a phenyl group, Or a mono-lower alkyl-substituted amino group, or substituted with a 6-membered saturated cyclic amino group.
  • a saturated cyclic amino group which may 6 membered and has, optionally substituted by hydroxyl C 6 - C io Ariru group in which force ,, or a benzene ring condensed with or 5-6 membered also It means a saturated or unsaturated heterocyclic group.
  • R 9a2 represents a lower alkyl group, a power which is a cycloalkyl group which may be substituted with lower alkyl, or a 5-membered saturated cyclic ester residue which may be substituted with lower alkyl.
  • R 9 a3 represents a 5-membered saturated or unsaturated cyclic ester residue or cyclic carbonate residue which may be substituted with lower alkyl or condensed with a benzene ring, and p is 0 or 1. It is an integer. )
  • the compound (I) of the present invention can be divided into two groups having a common main structure but different characteristics.
  • the first group is a proline derivative represented by the following formula (I-A) or a salt thereof, wherein Y is a substituent W (hydrogen atom or amino protecting group).
  • w is a hydrogen atom or an amino protecting group, and the definitions of other substituents and symbols are the same as those defined above.
  • the second group is a proline derivative (IB) or a salt thereof, wherein Y is represented by the formula (b). '
  • Compound (I-A) is an intermediate for producing compound (I_B), and among compounds (I-B), compounds in which R 9 is H or R 9a [hereinafter, referred to as compound (I-B) ' Has a strong antibacterial effect, especially against multidrug-resistant bacteria such as MRSA, and is useful as an antibacterial agent.
  • the structural features of the compound (IB) include (i) the presence of ring A, (ii) having at least three heterocyclic groups consisting of ring A, ring B, and ring C, (Iii) ring A and ring B are linked via T; (iv) N-formyl-N- ⁇ R 9 _ amine moiety; (V) substituent R 8 is present And the combination of these, especially (i), (ii) and (iii), above all, (i) is the essence of the feature.
  • a compound suitable as an antibacterial agent is represented by the following general formula (I-C) wherein R 9 in the general formula (I-B) is H and ring A is a ring. It is a phosphorus derivative or a salt thereof represented.
  • R 2 , R 3 , R 4 , R 5 , n, 1, p 2, p 3 and R 8 are the same as those defined in claim 1, and the ring has 1 to 3 rings.
  • Z 2 , Z 3 and Z 4 are the same or different and are atoms selected from a carbon atom (CH 2 , CH or C), a nitrogen atom (NH or N), a zeolite atom and an oxygen atom.
  • Z 1 Z 2 , Z 3 and Z 4 may be absent, and Ri, R 2 and R 3 may be bonded to any of the ring-forming carbon or nitrogen atoms. shall have.
  • R 6al and R 7Al are the same or different, a hydrogen atom, a lower alkyl group, a c androgenic atom or a lower alkoxy group, X al is TansoHara (CH 2, CH or C) means or an oxygen atom.)
  • a compound particularly suitable as an antibacterial agent is a proline derivative represented by the following general formula (I-D) or a salt thereof.
  • R 8 is the same as defined above, U is a nitrogen atom or a sulfur atom, R la is a hydrogen atom, a lower alkyl group, a lower alkoxy group or a halogen atom, and the two parts of Z are (It means the absence of a single bond, a double bond or a bond, so the Ala ring is 5 or 6 members.)
  • the compound (IE) in which R 9 is R 9a and salts thereof also have excellent antibacterial activity.
  • Ring A in compound (I) of the present invention has 1 to 4 heteroatoms as ring-constituting atoms, and may be condensed with a benzene ring which may be substituted with a halogen atom.
  • the hetero atom is selected from, for example, a nitrogen atom, an iodine atom or an oxygen atom, and preferably contains at least one nitrogen atom.
  • Ring A may be saturated, but is preferably unsaturated.
  • Ring A and ring B are linked via T, but nitrogen atom on ring B and carbon atom on ring A And a direct bond (hereinafter, referred to as an “N—C bond”, in which case T is a single bond).
  • Ring A Specific examples of the 5- to 6-membered heterocyclic group represented by Ring A include, but are not limited to, for example, pyridyl, pyrael, chenyl, furyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, piperidyl, tetrahydrofuryl and the like.
  • a condensed heterocyclic group obtained by condensing a heterocyclic group and a benzene ring is exemplified. Examples of such a fused heterocyclic group include isoquinolyl, quinolyl, quinoxalinyl, naphthyridinyl, benzothiazolyl, and benzoxazo
  • a nitrogen atom which is a hetero atom
  • the most preferred examples of such a heterocyclic group include pyrimidinyl and thiazolyl.
  • R 2 and R 3 in the compound (I) of the present invention may be substituted at any position of the ring A, but preferably binds to a carbon atom on the ring A.
  • R 2 and R 3 include, as one substituent, a lower alkyl group which may be substituted with 1 to 3 halogen atoms or a hydroxy group (the hydroxy group may be protected with acyl).
  • the term “lower” means that the hydrocarbon moiety of the group to which this term is attached has 1 to 6 carbon atoms, unless otherwise specified.
  • lower alkyl examples include straight or branched ones such as methyl, ethyl, propylyl, isopropyl, butyl, isobutyl, -butyl, pentyl, and hexyl.
  • halogen atom means fluorine, chlorine, bromine, and iodine.
  • the “lower alkyl group substituted with 1 to 3 halogen atoms” includes, for example, trifluoromethyl.
  • acyl examples include lower aliphatic acyl groups such as acetyl, propionyl, and piperoyl.
  • lower alkoxy is a lower alkyloxy group whose lower alkyl moiety has the above-mentioned meaning, and includes, for example, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy and the like.
  • the “lower alkylthio group” is a lower alkylthio group in which the lower alkyl moiety has the above-mentioned meaning, such as methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, monobutylthio, pentylthio, and hexylthio. And straight-chain or branched ones.
  • the “mono-lower alkylamino” is a mono-lower alkylamino group whose lower alkyl moiety has the above-mentioned meaning, for example, methylamino, ethylamino, propylamino, isopropylamino, butylamino, isoptylamino, —butylamino, pentylamino. And linear or branched ones such as hexylamino.
  • the “di-lower alkylamino” is a di-lower alkylamino group in which the lower alkyl moiety has the above-mentioned meaning, for example, dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, diisobutylamino. And linear or branched ones such as, di-butylamino, dipentylamino, and dihexylamino.
  • mono-lower alkylaminocarbonyl is a mono-lower alkylaminocarbonyl group having a lower alkyl moiety having the above-mentioned meaning, for example, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl.
  • examples thereof include linear or branched ones such as bonyl, isopropylaminocarbonyl, butylaminocarbonyl, isobutylaminocarbonyl, t-butylaminocarbonyl, pentylaminocarbonyl, and hexylaminocarbonyl.
  • di-lower alkylaminocarbonyl is a di-lower alkylaminocarbonyl group in which the lower alkyl moiety has the above-mentioned meaning, for example, dimethylaminocarbonyl, getylaminocarbonyl, dipropylamino Minocarbonyl, diisopropylaminocarbonyl, dibutylaminopropyl, diiso Linear or branched ones such as butylaminopropyl, di-pentylaminopropyl, dipentylaminopropyl, dihexylaminocarbonyl and the like can be mentioned.
  • hydroxy lower alkylamino is a hydroxy lower alkylamino group whose lower alkyl moiety has the above-mentioned meaning, for example, hydroxymethylamino, 2-hydroxyethylamino, 3-hydroxy Propylamino, 2-hydroxy-1-methyl-1-ethaneamine, 4-hydroxybutylamino, 2-hydroxy-1-methyl-1-propanamine, 2-hydroxy-1,1,1-dimethyl-1-ethaneamine, 5-hydroxypentylamino And linear or branched ones such as 6-hydroxyhexylamino.
  • lower alkoxycarbonyl is a lower alkoxycarbonyl group whose lower alkyl moiety has the above-mentioned meaning, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, Examples thereof include linear or branched ones such as butoxycarbonyl, t-butoxycarbonyl, pentyloxycarbonyl, and hexyloxycarbonyl.
  • lower alkylcarbonyloxy refers to a lower alkylcarbonyloxy having a lower alkyl moiety having the above-mentioned meaning, and includes methylcaplonoxy, ethylcarbonyloxy, propylcarbonyloxy, and isopropoxy. Examples thereof include linear or branched ones such as pyroxycarbonyl, butylcarbonyloxy, isobutylcarbonyloxy, -butylcarbonyloxy, pentylcarbonyloxy, and hexylcarbonyloxy.
  • the “lower alkylsulfonyloxy group” is a lower alkylsulfonyloxy group in which the lower alkyl moiety has the above-mentioned meaning, such as methylsulfonyloxy, ethylsulfonyloxy, propylsulfonyloxy, and isopropanol. Examples thereof include linear or branched ones such as pyrsulfonyloxy, butylsulfonyloxy, isoptylsulfonyloxy, -butylsulfonyloxy, pentylsulfonyloxy, and hexylsulfonyloxy.
  • the “lower alkylsulfonyloxy group substituted with 1 to 3 halogen atoms” includes trifluoro A methylsulfonyloxy group is exemplified.
  • examples of the “imino lower alkylene group” include —NH (CH 2 ) q — (Q is an integer of 1 to 6)
  • an iminomethylene group is preferable.
  • examples of the “oxy lower alkylene group” include 1 O (CH 2 ) g ⁇ (q is an integer of 1 to 6), and an oxymethylene group is preferable.
  • phenyl lower alkyloxy group is a phenyl lower alkyloxy group whose lower alkyl moiety has the above-mentioned meaning, and is a linear or branched such as benzyloxy, phenethyloxy, 3_phenylpropyloxy and the like.
  • Examples of the saturated cyclic group formed by combining R 6 and R 7 include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • the terms “the amino group is protected”, “optionally protected amino group” or “amino protecting group” are used.
  • protecting group for amino group those commonly used in the field of chemistry, particularly in the field of peptide chemistry are used.
  • Examples of the “protecting group for an amino group” include those capable of reductive elimination and those capable of hydrolytic elimination.
  • Examples of the "protecting group for an amino group” that can be reductively eliminated include an arylsulfonyl group such as P-toluenesulfonyl; a methyl group substituted by phenyl or benzyloxy such as benzyl, trityl and benzyloxymethyl; Benzyloxycarbonyl ⁇ arylmethoxycarbonyl such as P-methoxybenzyloxycarbonyl; halogenoethoxycarbonyl groups such as 2,2,2-trichloromouth ethoxycarbonyl and 2-thioethoxycarbonyl.
  • the “protecting group for the amino group” that can be hydrolytically removed includes ethoxycarponyl ⁇ B0C ⁇ butoxycarbonyl, benzyloxycarponyl, ⁇ -methoxybenzyloxycarponyl, vinyloxycarponyl And oxycarbonyl groups such as 2-tosylethoxycarbonyl; carbonyl groups such as formyl, acetyl, 1, and rifluoroacetyl; and ⁇ -ditrophenylsulfenyl, 1, rimethylsilyl.
  • Tetrahydropi Ranyl, diphenylphosphinyl and the like are exemplified.
  • amino group protecting group When two amino groups are present in the same molecule, one is an “amino group protecting group” that can be hydrolytically eliminated, and the other is an “amino group protecting group” that can be reductively eliminated. It is a good idea to adopt it.
  • the “protecting group for the amino group” in the “amino group or aminolponyl group (the amino group is protected)” for R 2 or R 3 those that can be reductively eliminated are used. It is preferable to select a “protecting group for an amino group” that can be hydrolytically eliminated as an amino protecting group for Y.
  • Examples of the “5- to 6-membered saturated or unsaturated cyclic group (a)” for R 3 include, but are not limited to, phenyl, adamantyl, pyridyl, piperazinyl, morpholinyl, morpholino, pyrazinyl, tetrahydro Examples thereof include a furyl group and the like, and these cyclic groups (a) may be substituted with a lower alkyl group such as methyl or ethyl or a halogen atom. These cyclic groups (a) are bonded to the ring A via a direct bond; a carboxylic acid; an imino lower alkylene such as iminomethylene; or an oxy lower alkylene such as oxymethylene.
  • alkyl group defined as R 8 may be linear or branched as long as it has 2 to 10 carbon atoms, but is preferably linear. Preferred alkyl groups are those having 4 to 7 carbon atoms, particularly preferably 13-butyl or 3-pentyl. Examples of cycloalkyl in “cycloalkyl lower alkyl” defined as R 8 include those having 4 to 7, preferably 5 or 6 carbon atoms, and lower alkyl having 1 to 4 carbon atoms. , Preferably methyl or ethyl. Accordingly, specific examples of suitable “cycloalkyl lower alkyl” include a cyclobenzylmethyl group and a cyclohexylmethyl group.
  • the “hydroxy protecting group” defined as R 9 is not particularly limited as long as it can be eliminated by chemical means, and examples include benzyl and 2,4-dimethoxyphenylmethyl. Of these, 2,4-dimethoxyphenylmethyl which is easily desorbed is preferred.
  • the compound having a hydroxy protecting group (I-B) has no antibacterial activity.
  • a lower alkyl group defined as R 9al (the lower alkyl group may be one or two selected from a phenyl group, a protected amino group and a carbonyl group); May be substituted with a group) ”, for example, include a methyl group, a -butyl group, a 3-force propyloxy group, a 2-phenyl-1-(-butoxycarponyl) aminoethyl group, and the like.
  • R 9al Specific examples of the “mono-lower alkyl-substituted amino group” or the “6-membered saturated cyclic amino group which may be substituted with a 6-membered saturated cyclic amino group” for R 9al include -butylamino, 4-piperidinyl-1- And a piperidinyl group. Specific examples of the "C 6 -C 10 aryl group optionally substituted with a hydroxyl group” for R 9al include a phenyl group, a 2-hydroxyphenyl group, a 1- or 2-naphthyl group, and the like.
  • 5- or 6-membered saturated or unsaturated heterocyclic group which may be condensed with a ring
  • 3-pyridyl 2-pyrrolyl, 3-quinolyl, 2-indolyl
  • 2- Examples include a phenyl group, a 3-furyl group, and a morpholino group.
  • lower alkyl group and the “cycloalkyl group optionally substituted with lower alkyl” for R 9a2 include isopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 2-isopropyl-5 -Methylcyclohexyl group.
  • a group represented by the following formula (c) is substituted with “lower alkyl” in R 9a3 .
  • Examples of the 5-membered saturated or unsaturated cyclic ester residue or cyclic carbonate residue which may be condensed with a benzene ring include groups represented by the following formulas (d) and (e). Is mentioned.
  • the compound (I) of the present invention can form an acid addition salt between a basic nitrogen atom in the molecule and an acid.
  • the acid addition salt include salts with an organic acid such as tartaric acid, fumaric acid, acetic acid, lactic acid, succinic acid, methanesulfonic acid, maleic acid, malonic acid, dalconic acid, and aspartic acid, or hydrochloric acid And salts with inorganic acids such as phosphoric acid and the like.
  • a metal salt such as sodium, potassium or calcium may be formed.
  • the compound (I) of the present invention sometimes exists as a hydrate or solvate, or as a stereoisomer such as an optical isomer or a mixture thereof, and all of them are included in the present invention. Is done.
  • Step 1 is a step of reacting compound (1) with compound (2) (amidation reaction) to form a new compound (IA-1).
  • This step can be performed according to a conventional method for peptide production. For example, this step is carried out in the presence of a condensing agent such as 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (WSC) and a reaction accelerator such as 1-hydroxybenzotriazole. It can be carried out by mixing and stirring both starting compounds in a solvent such as methylene.
  • the reaction is preferably performed in the presence of a base such as triethylamine. This step is performed at -10 ° C to 45 ° C for 1 hour to 3 days.
  • the compound (1) is known, and the compound (2) is mostly known, and can be easily prepared from a known compound by a known method.
  • Step 2 is a step of removing the amino protecting group W ′ of the compound (I-A-1) produced in Step 1 to give the compound (I-A-2).
  • Elimination can be carried out reductively or hydrolytically, depending on the nature of the amino protecting group W '. Usually, it is preferably carried out by hydrolysis, preferably by acid decomposition, and it is good to select an amino protecting group W ′ suitable for acid decomposition. Boc is suitable as W ′ suitable for acid decomposition.
  • the elimination of the amino-protecting group W 'by acidolysis can be carried out by contacting the compound (I-A-1) with an acid in a solvent at ⁇ 10 ° C. to 100 ° C., preferably 0 ° C. to room temperature. Can be implemented.
  • the acid include hydrogen chloride and trifluoroacetic acid
  • examples of the solvent include ethyl acetate, 1,4-dioxane, and methylene chloride.
  • Step 3 can be carried out by reacting compound (3) with compound (I-A-2) in the same manner as in step 1 (amidation reaction) to give compound (IB-1).
  • Compound (3) can be advantageously produced by the method described in Reference Examples below or a method analogous thereto.
  • Step 4 is to remove the hydroxyl-protecting group R 9 ′ of compound (I-B-1)
  • This step is carried out by adding an acid such as trifluoroacetic acid to the compound (I-B-1) in a solvent such as methylene chloride and mixing and stirring at 110 ° C. to 45 ° C. for 1 to 20 hours. it can.
  • Step 5 is a step of modifying the hydroxy group of (I-B-2) to give compound (I-E).
  • This step is a base such as the presence of pyridine, to (I- B- 2), for example, 9aR to ⁇ - teeth 1, J 9a2'0- C 0 "C 1, Rg a 3- ( by H 2 Bruno p - 1 (i ⁇ 9al, R9a2, ⁇ 3 and ⁇ are as defined above) or an alkylating agent such as an alkyl halide;
  • the compound of the present invention thus prepared can be converted to another compound of the present invention as appropriate, for example, by protecting Ri, R 2 , R 3 , R 6 or R 7 with “protection”.
  • the compounds produced in each step are characterized by 30 OMHz iH-NMR.
  • Compounds produced in Series D are amorphous unless otherwise specified and must be subjected to high performance liquid chromatography under the following conditions.
  • the physical properties may be clarified by the retention time of the raffle (the time from the injection of the compound of the present invention to the silica gel column to the discharge thereof).
  • 2,4,6-Triclo 1,1,3,5-triazine 2.04 g (11.1 mmo 1) of acetonitrile solution in 100 ml of acetonitrile solution 60 ml of an acetonitrile solution containing 6 mmo 1) and 2.5 g (25.2 mmo 1) of triethylamine was added dropwise and stirred at room temperature for 3 hours. After concentration, the mixture was extracted with chloroform to obtain 3.7 g of crude crystals.
  • the filtrate was concentrated under reduced pressure, a mixed solvent of diisopropyl ether and hexane was added to the obtained residue, and the mixture was stirred gently while cooling with ice, and the precipitated crystals were collected by filtration.
  • the filtrate was concentrated under reduced pressure to obtain 138.4 g of a crude product.
  • Example D 11 A compound (903 mg, 2.Ommo 1) was dissolved in 60 ml of ethyl acetate, and 4 molno 1000 ml of HC1 ethyl acetate solution 1.2 ml was dissolved in ice under ice-cooling. I got it. After concentration under reduced pressure, the precipitate was collected by filtration and dried to give 914 mg (91%) of the desired product.
  • Example D_1-1 The following compounds were obtained in the same manner as in the method described in Example D_1-1 or Example D-12.
  • the compound of Example D-2-1-1 was produced according to the method described in Example D-1-1-1.
  • Example D_1-1 The following compounds were obtained in the same manner as described in Example D_1-1 or Example D-11-10. However, D-4_3 was manufactured according to the method described in D-1-15, and D-16-3 was manufactured according to the method described in D-1-2. Further, the metal salt compound was produced according to the method described in Example D_1-1-1.
  • Example D A compound of 16-1 15 Omg (0.314 mmol), triethylamine 881 (0.63 mmol) and toluene 2. A mixture of Oml at room temperature was added with butyl isocyanate 43 1 (0.38 mm 0 1) was added, and the mixture was stirred at the same temperature for 23 hours.
  • Example D_1-1 The following compounds were obtained in the same manner as described in Example D_1-1 or Example D-11-14.
  • the compound of Example D- 25- 1- is the same as Example D-1-1 It was manufactured according to the method described.
  • Example D-110 To the compound 15 Omg (0.25 lmmo 1) obtained in Example D-110, 5 ml of ethanol and 20% Pd (OH) 2 -C 3 Omg were added, and the mixture was stirred at room temperature for 7 hours under a hydrogen atmosphere. .
  • the compound (I-B) ′ of the present invention thus obtained has an excellent antibacterial activity and is useful as an antibacterial agent.
  • Antibacterial activity in vitro (MIC: gZm 1): The minimum inhibitory concentration (MIC: g / m 1) was measured according to the standard method defined by The National Committee for Clinical Laboratory Standards (NCCLS). 40 results were obtained.
  • NCCLS National Committee for Clinical Laboratory Standards
  • Strain M Mor axel la (B.) catarrhal is K1209 3 ' 4
  • Compound A has the structure described in Section 2 of the present specification and is a comparative control compound disclosed in Example 12 of WO99 / 39704 pamphlet.
  • Compound B is a commercially available pyridonecarboxylic acid antibacterial agent (ciprofloxacin) having the following structure.
  • This strain is a clinical isolate.
  • This strain is a Gram-negative bacterium, the others are Gram-positive.
  • the strains H to K were measured by the microfluidic dilution method, and the other strains were measured by the agar plate dilution method.
  • Experimental example 2 Effect on mouse systemic infection:
  • mice ICR-strain male mice (body weight about 20 g) in 50% infection lethal dose of about 50 times the amount of the pathogen per animal (A to The live bacteria of C) were intraperitoneally administered (ip) to cause infection, and the test compound dissolved in physiological saline was subcutaneously administered (sc) twice at 1 hour and 4 hours after infection, and 7 days after infection Was calculated by the probit method from the survival rate of the mice.
  • the results are shown in Table 41. Antibacterial action on the table 41 systemic infections (ED 5:. Mg / kg / do se)
  • Table 40 refers to the same strain from ⁇ above, salts among, which 9 is hydrogen atom or 1 9 £ 1 Dearu compound (1 -B) 'or a physiologically acceptable compounds of the present invention It has excellent antibacterial activity and low toxicity.
  • the compound of the present invention has better antibacterial activity in vitro than compound A, and also has a strong antibacterial activity in vivo.
  • D-1-1, D-3-1, D-7-1, D-14, D-15, D-16-1, D-17, D-25 _ 1 and D-54 The acute toxicity values (LD50, iV) for the compounds in mice are all> 100 mg / kg, and these compounds are non-toxic or extremely low.
  • the compound (I-B) ′ of the present invention or a physiologically acceptable salt thereof is useful as an antibacterial agent for humans and animals.
  • the dose of the compound (I_B) 'of the present invention varies depending on the administration method, symptoms, age, etc., but is usually about 2 to 5000 mg, preferably about 5 to 500 mg, particularly preferably about 5 to 500 mg per 60 kg of body weight per day. 30-30 Omg.
  • the route of administration may be oral, but parenteral, especially intravenous, is recommended.
  • the compound (I-B) ′ of the present invention is generally administered in the form of a preparation. These preparations can be prepared by mixing the compound (I-B) 'with the components to be formulated.
  • a solvent such as water or physiological saline is an essential component, and in addition, a tonicity agent, a soothing agent, a pH regulator, a buffer, a storage agent, and the like.
  • auxiliary components such as agents are appropriately blended.
  • Liquid preparations such as injections can be prepared by dissolving compound (I-B) 'in a solvent such as physiological saline for injection, and adding other auxiliary components before or after dissolution as required.
  • Lyophilized formulations can be prepared by lyophilizing such solutions and redissolving them upon administration.
  • the compound (IB) ′ of the present invention or a physiologically acceptable salt thereof has an excellent action on multidrug-resistant bacteria and is useful as an antibacterial agent. Further, the compound (IA) or a salt thereof of the present invention is useful as a direct intermediate for producing the compound (IB).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des dérivés de proline représentés par la formule générale (I) ou leurs sels, utiles en tant que médicaments antibactériens dirigés contre des bactéries multirésistantes aux antibiotiques. Dans la formule (I), A représente un groupe dérivé d'un hétérocycle à 5 ou 6 éléments qui peut fusionner avec un noyau benzène éventuellement halogéné ; p1, p2 et p3 représentent chacun un entier de valeur 0 ou 1 ; R1, R2 et R3 représentent chacun H, alkyle inférieur éventuellement substitué, un groupe cyclique saturé ou insaturé à 5 ou 6 éléments (a) ou analogue ; T représente une liaison simple, méthylène ou carbonyle ; R4 et R5 représentent chacun H, alkyle inférieur, ou analogue ; n et m représentent chacun un entier de valeur 1 ou 2 ; R6 et R7 représentent chacun H, OH, halogéno, ou analogue ; X représente C, S ou O ; Y représente H, un groupe de protection amino, ou un groupe représenté par la formule générale (b) ; R8 représente alkyle ou alkyle inférieur cycloalkyle ; et R9 représente H, un groupe de protection hydroxyle, ou analogue. Des composés dans lesquels Y représente H ou un groupe de protection amino correspondent à des intermédiaires de composés dans lesquels Y représente un groupe représenté par la formule générale (b).
PCT/JP2003/010548 2002-08-23 2003-08-21 Derive de proline Ceased WO2004018453A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003257637A AU2003257637A1 (en) 2002-08-23 2003-08-21 Proline derivatives

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2002242795A JP2006052138A (ja) 2002-08-23 2002-08-23 プロリン誘導体
JP2002/242795 2002-08-23
JP2002/339200 2002-11-22
JP2002339200A JP2006052139A (ja) 2002-11-22 2002-11-22 プロリン誘導体
JP2003/27010 2003-02-04
JP2003027010A JP2006052140A (ja) 2003-02-04 2003-02-04 プロリン誘導体

Publications (1)

Publication Number Publication Date
WO2004018453A1 true WO2004018453A1 (fr) 2004-03-04

Family

ID=31950449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/010548 Ceased WO2004018453A1 (fr) 2002-08-23 2003-08-21 Derive de proline

Country Status (3)

Country Link
AU (1) AU2003257637A1 (fr)
TW (1) TW200410956A (fr)
WO (1) WO2004018453A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032322A1 (fr) * 2004-09-20 2006-03-30 4Sc Ag NOUVEAUX INHIBITEURS HÉTÉROCYCLIQUES DU NF-κB
JP2007517010A (ja) * 2003-12-24 2007-06-28 プロシディオン・リミテッド Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
JP2008513499A (ja) * 2004-09-20 2008-05-01 ゼノン・ファーマシューティカルズ・インコーポレイテッド ステアロイル−ＣｏＡデサチュラーゼ酵素によって媒介される疾患の処置のための複素環誘導体
JP2009502948A (ja) * 2005-07-26 2009-01-29 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌・殺カビ性カルボキサミド
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
US7723349B2 (en) 2003-04-24 2010-05-25 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
US7812041B2 (en) 2004-09-20 2010-10-12 4Sc Ag Heterocyclic NF-κB inhibitors
US8680114B2 (en) 2003-11-21 2014-03-25 Array Biopharma, Inc. AKT protein kinase inhibitors
AU2011265309B2 (en) * 2003-11-21 2014-06-05 Array Biopharma, Inc. AKT protein kinase inhibitors
CN104119296A (zh) * 2013-04-25 2014-10-29 苏州科捷生物医药有限公司 一种2-三氟甲基-5-哌嗪基-噻二唑的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039704A1 (fr) * 1998-02-07 1999-08-12 British Biotech Pharmaceuticals Limited Agents antibacteriens
WO2000058294A1 (fr) * 1999-03-29 2000-10-05 British Biotech Pharmaceuticals Limited Agents antibacteriens
WO2002083628A1 (fr) * 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. Composes benzo-fusionnes a disubstitution en positions 1,4

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039704A1 (fr) * 1998-02-07 1999-08-12 British Biotech Pharmaceuticals Limited Agents antibacteriens
WO2000058294A1 (fr) * 1999-03-29 2000-10-05 British Biotech Pharmaceuticals Limited Agents antibacteriens
WO2002083628A1 (fr) * 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. Composes benzo-fusionnes a disubstitution en positions 1,4

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723349B2 (en) 2003-04-24 2010-05-25 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
US9801877B2 (en) 2003-04-24 2017-10-31 Incyte Corporation AZA spiro alkane derivatives as inhibitors of metalloproteases
US9403775B2 (en) 2003-04-24 2016-08-02 Incyte Corporation AZA spiro alkane derivatives as inhibitors of metalloproteases
US10226459B2 (en) 2003-04-24 2019-03-12 Incyte Holdings Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
AU2011265309B2 (en) * 2003-11-21 2014-06-05 Array Biopharma, Inc. AKT protein kinase inhibitors
US8680114B2 (en) 2003-11-21 2014-03-25 Array Biopharma, Inc. AKT protein kinase inhibitors
JP2007517010A (ja) * 2003-12-24 2007-06-28 プロシディオン・リミテッド Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
WO2006032322A1 (fr) * 2004-09-20 2006-03-30 4Sc Ag NOUVEAUX INHIBITEURS HÉTÉROCYCLIQUES DU NF-κB
US7812041B2 (en) 2004-09-20 2010-10-12 4Sc Ag Heterocyclic NF-κB inhibitors
EP2289510A1 (fr) * 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques pour le traitement des maladies induites par des enzymes stearoyl-coa desaturase
US8106048B2 (en) 2004-09-20 2012-01-31 4Sc Ag Heterocyclic NF-κB inhibitors
EP1830837B1 (fr) * 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Derives heterocycliques pour le traitement de maladies induites par des enzymes stearoyl-coadesaturases
EA012607B1 (ru) * 2004-09-20 2009-10-30 4Сц Аг НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
JP2008513499A (ja) * 2004-09-20 2008-05-01 ゼノン・ファーマシューティカルズ・インコーポレイテッド ステアロイル−ＣｏＡデサチュラーゼ酵素によって媒介される疾患の処置のための複素環誘導体
JP2008513386A (ja) * 2004-09-20 2008-05-01 ４エスシー アーゲー 新規な複素環式ＮＦ−κＢ阻害剤
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
JP2009502948A (ja) * 2005-07-26 2009-01-29 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌・殺カビ性カルボキサミド
US8586611B2 (en) 2005-07-26 2013-11-19 E. I. Du Pont De Nemours And Company Fungicidal carboxamides
CN104119296A (zh) * 2013-04-25 2014-10-29 苏州科捷生物医药有限公司 一种2-三氟甲基-5-哌嗪基-噻二唑的合成方法

Also Published As

Publication number Publication date
TW200410956A (en) 2004-07-01
AU2003257637A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
CN112778284B (zh) 一种嘧啶并环衍生物及其在医药上的应用
EP3634958B1 (fr) Agonistes du récepteur 2 du peptide formylé et agonistes du récepteur 1 du peptide formylé à base de cyclopropyle d'urée
DE60218511T2 (de) Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
ES2316784T3 (es) Derivados de 2-hidroxi-3-heteroarilindol como inhibidores de gsk3.
TWI573786B (zh) 吡咯啶衍生物
JP3461441B2 (ja) 芳香族アミジン誘導体又はその塩及びその製造中間体
AU2005321475B2 (en) Organic compounds
JP4861306B2 (ja) Ｘａ因子阻害剤としてのピロール誘導体
EP2989088B1 (fr) Dérivés de dolastatine 10 et d'auristatines
US7622471B2 (en) Pyrazole derivatives having a pyridazine and pyridine functionality
EP1558247B1 (fr) Derives de benzimidazole
EA010165B1 (ru) Производные индазола
JP3457694B2 (ja) インフルエンザ感染予防・治療薬
HU227882B1 (hu) Prolinszármazékok és gyógyszerként való alkalmazásuk
KR20100033541A (ko) 멜라노코르틴-4 수용체 모듈레이터로서의 치환된 헤테로아릴피페리딘 유도체
AU2009315448B2 (en) Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof
EA009121B1 (ru) Бета-карболины, применяемые для лечения воспалительных заболеваний
KR100238562B1 (ko) 피페리딘 유도체 화합물
WO2004018453A1 (fr) Derive de proline
CN113248492B (zh) 杂环取代的含氮六元杂环衍生物及其制法与医药上的用途
JPH02502455A (ja) ピリドンカルボン酸または酸誘導体を含有する抗生物質β‐ラクタム
WO1998034936A1 (fr) Composes de carbapenem, leur utilisation et composes intermediaires de celui-ci
EP4598914A1 (fr) Protac utiles contre la protéase principale sars-cov-2
JP2006052138A (ja) プロリン誘導体
EA012266B1 (ru) Сульфониламиноциклические соединения и их применение

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP